In line with the PLATO trial [ 16 ], we observed a strong trend towards higher levels of uric acid and a greater incidence of hyperuricemia in ACS patients receiving ticagrelor as compared with prasugrel-treated patients.
1
—
—
In line with the PLATO trial [ 16 ], we observed a strong trend towards higher levels of uric acid and a greater incidence of hyperuricemia in ACS patients receiving ticagrelor as compared with prasugrel-treated patients.